Sign in Subscribe
Cancer

Evaluation of Feasibility of Response Adapted Stereotactic Ablative Body Radiotherapy in Melanoma

Strategic Insights

— 1 min read

Researchers at the Icon Cancer Foundation have initiated a clinical trial to evaluate the feasibility of response-adapted or response-and-anatomical-adapted Stereotactic Ablative Body Radiotherapy (SABR) in patients with advanced melanoma receiving immunotherapy. The trial, registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) as ACTRN12624001299594, aims to develop a method for using SABR that accounts for both anatomical and biological responses to immunotherapy. The principal investigator of the trial is A/Prof Matthew Foote, and the study type is Interventional.

Key Takeaways:

  • The ERASE trial pilots Part A and B aim to establish and test the planning and treatment workflow for delivering response-and-anatomical-adapted SABR.
  • The trial will evaluate the feasibility of using SABR in patients with advanced melanoma receiving immunotherapy.
  • Participants will receive either standard of care (immunotherapy with immune checkpoint inhibitors) without SABR or one to three rounds of SABR to up to 5 new or SABR-naïve lesions.
  • Treatment with SABR will be based on the participant's response to immunotherapy at 3, 6, and 9 months after commencement.
  • The trial aims to minimize the radiation dose delivered to nearby organs while potentially increasing the doses of radiation delivered to metastatic lesions.
  • The personalized approach could avoid over-treating patients who respond well to immunotherapy and allow for higher doses for patients who don't respond as well.
  • A/Prof Matthew Foote is the principal investigator of the trial.
  • The study type is Interventional.

Statistics:

  • Up to 5 metastases will be treated with SABR.
  • Participants will have MRI scans to determine their eligibility for the trial.
  • Lesions will be treated with SABR based on their response to immunotherapy at 3, 6, and 9 months after commencement.
  • Up to 3 rounds of SABR may be delivered to new or SABR-naïve lesions.

Sources:

  • Australian New Zealand Clinical Trials Registry (ANZCTR)
  • ActRN12624001299594
  • Icon Cancer Foundation

Read more